Adherence to the evidence-based heart failure drug treatment: Are there sex-specific differences among new users?

The evidence-based heart failure (HF) drug treatment is made of a β-blocker and an angiotensin-converting enzyme inhibitor or an angiotensin II receptor blocker, or hydralazine + isosorbide dinitrate. Little is known about sex-based difference in adherence to the evidence-based HF drug treatment.

Source: Research in Social and Administrative Pharmacy - October 25, 2017 Category: Pharmaceuticals Authors: J.F. Kayibanda, C. Girouard, J.-P. Gr égoire, E. Demers, J. Moisan Source Type: research